AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reaffirmed by J P Morgan Chase & Co in a research note issued to investors on Friday.

Other equities research analysts have also recently issued reports about the company. BNP Paribas reiterated a “neutral” rating and issued a GBX 5,300 ($69.21) price objective on shares of AstraZeneca plc in a report on Monday, April 3rd. UBS AG set a GBX 5,150 ($67.25) price objective on AstraZeneca plc and gave the stock a “neutral” rating in a report on Wednesday, April 5th. HSBC Holdings plc restated a “reduce” rating and set a GBX 4,200 ($54.84) target price on shares of AstraZeneca plc in a report on Friday, May 5th. Shore Capital restated a “sell” rating on shares of AstraZeneca plc in a report on Wednesday, May 10th. Finally, Berenberg Bank boosted their target price on AstraZeneca plc from GBX 5,670 ($74.04) to GBX 5,850 ($76.39) and gave the stock a “buy” rating in a report on Wednesday, May 17th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of GBX 5,251.80 ($68.58).

Shares of AstraZeneca plc (LON AZN) traded up 0.57% during trading on Friday, reaching GBX 5152.00. The company had a trading volume of 1,577,047 shares. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00. The company’s market capitalization is GBX 65.22 billion. The stock’s 50-day moving average price is GBX 5,235.89 and its 200-day moving average price is GBX 4,847.81.

TRADEMARK VIOLATION WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with's FREE daily email newsletter.